Kuncman, Ł.; Orzechowska, M.; Stawiski, K.; Masłowski, M.; Ciążyńska, M.; Gottwald, L.; Milecki, T.; Fijuth, J.
The Kinetics of FMS-Related Tyrosine Kinase 3 Ligand (Flt-3L) during Chemoradiotherapy Suggests a Potential Gain from the Earlier Initiation of Immunotherapy. Cancers 2022, 14, 3844.
https://doi.org/10.3390/cancers14163844
AMA Style
Kuncman Ł, Orzechowska M, Stawiski K, Masłowski M, Ciążyńska M, Gottwald L, Milecki T, Fijuth J.
The Kinetics of FMS-Related Tyrosine Kinase 3 Ligand (Flt-3L) during Chemoradiotherapy Suggests a Potential Gain from the Earlier Initiation of Immunotherapy. Cancers. 2022; 14(16):3844.
https://doi.org/10.3390/cancers14163844
Chicago/Turabian Style
Kuncman, Łukasz, Magdalena Orzechowska, Konrad Stawiski, Michał Masłowski, Magdalena Ciążyńska, Leszek Gottwald, Tomasz Milecki, and Jacek Fijuth.
2022. "The Kinetics of FMS-Related Tyrosine Kinase 3 Ligand (Flt-3L) during Chemoradiotherapy Suggests a Potential Gain from the Earlier Initiation of Immunotherapy" Cancers 14, no. 16: 3844.
https://doi.org/10.3390/cancers14163844
APA Style
Kuncman, Ł., Orzechowska, M., Stawiski, K., Masłowski, M., Ciążyńska, M., Gottwald, L., Milecki, T., & Fijuth, J.
(2022). The Kinetics of FMS-Related Tyrosine Kinase 3 Ligand (Flt-3L) during Chemoradiotherapy Suggests a Potential Gain from the Earlier Initiation of Immunotherapy. Cancers, 14(16), 3844.
https://doi.org/10.3390/cancers14163844
